
Humanigen launches Managed Access Program for lenzilumab
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company specializing in the prevention and treatment of an overactive immune response called “cytokine shock,” today announced that lenzilumab is now available for select patients. patients with COVID-19 through its new Managed Access Program (“LenzMAP™”). Clinigen Group plc (“Clinigen”), a global pharmaceuticals and services company, is currently implementing…